The CEO is good at presenting but I have few concerns:
- sales growth in oz are too slow
- the CEO mentioned "several 100's of sites in the US are currently trialling the product". The update on the 18 March only describes 7 trial sites and 1 study site. A bit wishful thinking perhaps.
- sales growth in USA are too slow.
- introducing new potential areas of development is just confusing the message at this stage imo (ie gps tracker, falls alert, positional nursing, dehydration tracker, smart diagnostics, etc). All these are useless if the primary product does not sell for its intended purpose.
They need a CR by June, so I guess this is just the CEO doing her job of beating the drum.
SVA Price at posting:
50.0¢ Sentiment: Sell Disclosure: Not Held
